|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
NZ250844A
(en)
|
1993-04-07 |
1996-03-26 |
Pfizer |
Treatment of non-insulin dependant diabetes with peptides; composition
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
US5641757A
(en)
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
|
EP2016950B1
(en)
|
1996-08-08 |
2011-01-05 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical composition comprising an exendin-4 peptide
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
ES2283025T3
(es)
|
1996-08-30 |
2007-10-16 |
Novo Nordisk A/S |
Derivados de glp-1.1.
|
|
DE69831673C5
(de)
|
1997-01-07 |
2015-01-22 |
Amylin Pharmaceuticals, Llc |
Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6723530B1
(en)
|
1997-02-05 |
2004-04-20 |
Amylin Pharmaceuticals, Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
BR9811866A
(pt)
|
1997-08-08 |
2000-08-15 |
Amylin Pharmaceuticals Inc |
Compostos agonistas de exendina
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
BR9815670A
(pt)
|
1997-11-14 |
2000-10-17 |
Amylin Pharmaceuticals Inc |
Compostos agonistas de exendina
|
|
ATE383867T1
(de)
|
1997-11-14 |
2008-02-15 |
Amylin Pharmaceuticals Inc |
Neuartige exendin agonisten
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
DE69840106D1
(de)
|
1998-01-09 |
2008-11-20 |
Amylin Pharmaceuticals Inc |
Formulierungen für amylin peptidagonisten mit insulin
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
EP1950224A3
(en)
|
1998-03-09 |
2008-12-17 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
AU2612599A
(en)
|
1998-03-13 |
1999-10-11 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
|
EP1419783A3
(en)
|
1998-06-12 |
2005-01-12 |
Amylin Pharmaceuticals, Inc. |
Use of a composition comprising an exendin or a compound derived therefrom and a pharmaceutical carrier
|
|
US7056734B1
(en)
|
1998-08-10 |
2006-06-06 |
The United States Of America As Represented By The Department Of Health And Human Services, Nih |
Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
|
|
AU765584B2
(en)
|
1998-09-17 |
2003-09-25 |
Eli Lilly And Company |
Protein formulations
|
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
ATE307603T1
(de)
|
1998-12-22 |
2005-11-15 |
Lilly Co Eli |
Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
|
|
ES2244416T5
(es)
|
1999-01-14 |
2020-01-03 |
Amylin Pharmaceuticals Llc |
Formulaciones novedosas de agonistas de la exendina y métodos de administración de los mismos
|
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
PT1143989E
(pt)
|
1999-01-14 |
2007-03-30 |
Amylin Pharmaceuticals Inc |
Exendinas para supressão de glucagon
|
|
EP1956000B1
(en)
|
1999-03-17 |
2016-10-05 |
Novo Nordisk A/S |
Acylating agents useful for acylating peptides
|
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
|
JP2002544127A
(ja)
|
1999-04-30 |
2002-12-24 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
修飾されたエキセンジンおよびエキセンジン・アゴニスト
|
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
AU754770B2
(en)
|
1999-05-17 |
2002-11-21 |
Conjuchem Biotechnologies Inc. |
Long lasting insulinotropic peptides
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6482799B1
(en)
|
1999-05-25 |
2002-11-19 |
The Regents Of The University Of California |
Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
|
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US6972319B1
(en)
|
1999-09-28 |
2005-12-06 |
Bayer Pharmaceuticals Corporation |
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
US20030036504A1
(en)
|
2000-01-10 |
2003-02-20 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
|
|
JP2003526671A
(ja)
|
2000-03-14 |
2003-09-09 |
レストラゲン，インコーポレイテッド |
幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
|
|
WO2001087322A2
(en)
|
2000-05-17 |
2001-11-22 |
Bionebraska, Inc. |
Peptide pharmaceutical formulations
|
|
CN103356996A
(zh)
|
2000-05-19 |
2013-10-23 |
埃米林药品公司 |
Glp-1用于制备治疗急性冠脉综合征的药物的用途
|
|
US7138546B2
(en)
|
2000-08-18 |
2006-11-21 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US7507714B2
(en)
|
2000-09-27 |
2009-03-24 |
Bayer Corporation |
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
|
|
MXPA02006118A
(es)
|
2000-10-20 |
2004-08-23 |
Amylin Pharmaceuticals Inc |
Tratamiento de la invernacion del miocardio y cardiopatia diabetica con un peptido glp-1.
|
|
CN1483041A
(zh)
|
2000-12-07 |
2004-03-17 |
|
Glp-1融合蛋白
|
|
EP2186824A3
(en)
|
2000-12-13 |
2010-09-22 |
Eli Lilly & Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
GB2371227A
(en)
|
2001-01-10 |
2002-07-24 |
Grandis Biotech Gmbh |
Crystallisation - resistant aqueous growth hormone formulations
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
EP1542712A2
(en)
|
2001-06-01 |
2005-06-22 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
|
DK1412384T3
(da)
|
2001-06-28 |
2008-04-28 |
Novo Nordisk As |
Stabil formulering af modificeret GLP-1
|
|
EP1485707B1
(en)
|
2001-07-16 |
2009-01-14 |
caprotec bioanalytics GmbH |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
|
ATE408414T1
(de)
|
2001-07-31 |
2008-10-15 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
|
US7238663B2
(en)
|
2001-08-28 |
2007-07-03 |
Eli Lilly And Company |
Pre-mixes of GLP-1 and basal insulin
|
|
US7179788B2
(en)
|
2001-10-19 |
2007-02-20 |
Eli Lilly And Company |
Biphasic mixtures of GLP-1 and insulin
|
|
WO2003059934A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
AU2003208945B2
(en)
|
2002-02-20 |
2008-05-01 |
Emisphere Technologies, Inc |
Method for administering GLP-1 molecules
|
|
WO2003072060A2
(en)
|
2002-02-27 |
2003-09-04 |
Immunex Corporation |
Polypeptide formulation
|
|
US20040209255A1
(en)
|
2002-03-11 |
2004-10-21 |
Hk Pharmaceuticals, Inc. |
Compounds and methods for analyzing the proteome
|
|
US7141240B2
(en)
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
|
WO2003084563A1
(en)
|
2002-04-04 |
2003-10-16 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
|
US6861236B2
(en)
|
2002-05-24 |
2005-03-01 |
Applied Nanosystems B.V. |
Export and modification of (poly)peptides in the lantibiotic way
|
|
EP1515749B1
(en)
|
2002-06-14 |
2012-08-15 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
EP1525219B1
(en)
|
2002-07-04 |
2009-05-27 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
|
WO2004004780A1
(en)
|
2002-07-09 |
2004-01-15 |
Sandoz Ag |
Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
|
|
US20070065469A1
(en)
|
2002-07-09 |
2007-03-22 |
Michael Betz |
Liquid formulations with high concentration of human growth hormone (high) comprising glycine
|
|
US20040038865A1
(en)
|
2002-08-01 |
2004-02-26 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
CA2493478C
(en)
|
2002-08-01 |
2014-11-18 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
US20080260838A1
(en)
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
EP2058311A3
(de)
|
2002-08-21 |
2011-04-13 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
8-[3-amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
CA2500295A1
(en)
|
2002-10-02 |
2004-04-29 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
|
DK1583541T3
(da)
|
2002-11-20 |
2011-04-11 |
Neuronova Ab |
Forbindelser og fremgangsmåder til at øge neurogenese
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
US20040209803A1
(en)
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
JP2006514035A
(ja)
|
2002-12-17 |
2006-04-27 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
心不整脈の予防および治療
|
|
PL1620118T3
(pl)
|
2003-04-08 |
2014-11-28 |
Yeda Res & Dev |
Leki odwracalnie pegylowane
|
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
|
ATE549028T1
(de)
|
2003-05-15 |
2012-03-15 |
Tufts College |
Stabile analoga von glp-1
|
|
KR101128320B1
(ko)
|
2003-05-23 |
2012-04-12 |
넥타르 테라퓨틱스 |
아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
|
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
|
US8008255B2
(en)
|
2003-05-30 |
2011-08-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
CA2527743A1
(en)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
ATE529126T1
(de)
|
2003-06-03 |
2011-11-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische peptid zusammensetzungen
|
|
JP2007524592A
(ja)
|
2003-06-03 |
2007-08-30 |
ノボ・ノルデイスク・エー／エス |
安定化された薬学的ペプチド組成物
|
|
KR101308912B1
(ko)
|
2003-06-03 |
2013-09-23 |
노보 노르디스크 에이/에스 |
안정화된 약학적 펩티드 조성물
|
|
US8921311B2
(en)
|
2003-08-01 |
2014-12-30 |
Mannkind Corporation |
Method for treating hyperglycemia
|
|
EP2107069B1
(en)
|
2003-08-05 |
2013-01-16 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
RU2006103860A
(ru)
|
2003-08-21 |
2006-07-27 |
Ново Нордиск А/С (DK) |
Способ разделения полипептидов, содержащих рацемическую аминокислоту
|
|
WO2005021022A2
(en)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
US20060247167A1
(en)
|
2003-09-01 |
2006-11-02 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
JP2007537981A
(ja)
|
2003-09-19 |
2007-12-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規の血漿タンパク質親和性タグ
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
JP4800959B2
(ja)
|
2003-11-13 |
2011-10-26 |
ノヴォ ノルディスク アー／エス |
糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
|
|
US20050106214A1
(en)
|
2003-11-14 |
2005-05-19 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
US20050281879A1
(en)
|
2003-11-14 |
2005-12-22 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
WO2005081619A2
(en)
|
2003-11-20 |
2005-09-09 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
CN113304250A
(zh)
|
2003-11-20 |
2021-08-27 |
诺和诺德股份有限公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
|
AU2004295023A1
(en)
|
2003-12-03 |
2005-06-16 |
Novo Nordisk A/S |
Single-chain insulin
|
|
CA2549011A1
(en)
|
2003-12-10 |
2005-06-30 |
Nektar Therapeutics Al, Corporation |
Compositions comprising two different populations of polymer-active agent conjugates
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
CA2556226A1
(en)
|
2004-02-11 |
2006-08-10 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides and methods for making and using them
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
WO2005077094A2
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
CN1961000B
(zh)
|
2004-02-11 |
2011-05-04 |
安米林药品公司 |
具有可选择特性的杂合多肽
|
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
AU2004319756C1
(en)
|
2004-04-15 |
2014-02-20 |
Alkermes Pharma Ireland Limited |
Polymer-based sustained release device
|
|
US20060110423A1
(en)
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
US20090069226A1
(en)
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
WO2005117584A2
(en)
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
|
EP1758575A1
(en)
|
2004-06-11 |
2007-03-07 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
|
CN103223160B
(zh)
|
2004-07-19 |
2015-02-18 |
比奥孔有限公司 |
胰岛素-低聚物共轭物,制剂及其用途
|
|
JP2008507280A
(ja)
|
2004-07-21 |
2008-03-13 |
アンブレツクス・インコーポレイテツド |
非天然コードアミノ酸を用いた生合成ポリペプチド
|
|
CA2575756A1
(en)
|
2004-08-03 |
2006-02-16 |
Biorexis Technology, Inc. |
Combination therapy using transferrin fusion proteins comprising glp-1
|
|
ES2442223T3
(es)
|
2004-08-31 |
2014-02-10 |
Novo Nordisk A/S |
Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
JP2008513384A
(ja)
|
2004-09-17 |
2008-05-01 |
ノボ ノルディスク アクティーゼルスカブ |
インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物
|
|
WO2006039336A2
(en)
|
2004-10-01 |
2006-04-13 |
Ramscor, Inc. |
Conveniently implantable sustained release drug compositions
|
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー／エス |
遅延性のエキセンディン−４化合物
|
|
US7595294B2
(en)
|
2004-10-08 |
2009-09-29 |
Transition Therapeutics, Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
|
US20090036355A1
(en)
|
2004-10-13 |
2009-02-05 |
Sanjay Bhanot |
Antisense Modulation of PTP1B Expression
|
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
|
ES2735533T3
(es)
|
2004-11-12 |
2019-12-19 |
Novo Nordisk As |
Formulaciones estables de GLP-1
|
|
CN101056650A
(zh)
|
2004-11-12 |
2007-10-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
|
WO2006051103A2
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
CN101128487B
(zh)
|
2004-12-02 |
2012-10-10 |
杜门蒂斯有限公司 |
靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
|
|
SG158141A1
(en)
|
2004-12-13 |
2010-01-29 |
Amylin Pharmaceuticals Inc |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
|
ES2357089T5
(es)
|
2004-12-21 |
2014-02-24 |
Nektar Therapeutics |
Reactivos de tiol polimérico estabilizados
|
|
MX2007007565A
(es)
|
2004-12-22 |
2007-07-24 |
Lilly Co Eli |
Formulaciones de proteina de fusion analoga del peptido-1similar al glucagon (glp-1).
|
|
CA2599594A1
(en)
|
2004-12-24 |
2006-07-13 |
Amylin Pharmaceuticals, Inc. |
Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
EP1845105A4
(en)
|
2005-01-14 |
2009-02-18 |
Wuxi Grandchamp Pharmaceutical |
MODIFIED EXENDINES AND CORRESPONDING USES
|
|
WO2006082588A2
(en)
|
2005-02-07 |
2006-08-10 |
Pharmalight Inc. |
Method and device for ophthalmic administration of active pharmaceutical ingredients
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
JP2008530130A
(ja)
|
2005-02-11 |
2008-08-07 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
DK1888103T3
(da)
|
2005-04-11 |
2012-04-23 |
Amylin Pharmaceuticals Inc |
Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
|
|
WO2006114396A1
(en)
|
2005-04-24 |
2006-11-02 |
Novo Nordisk A/S |
Injection device
|
|
WO2006125763A1
(en)
|
2005-05-25 |
2006-11-30 |
Novo Nordisk A/S |
Stabilized polypeptide formulations
|
|
US8546326B2
(en)
|
2005-06-06 |
2013-10-01 |
Camurus Ab |
Glp-1 analogue formulations
|
|
ATE553124T1
(de)
|
2005-06-13 |
2012-04-15 |
Imp Innovations Ltd |
Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
|
|
GB0511986D0
(en)
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
BRPI0611872B8
(pt)
|
2005-06-16 |
2021-05-25 |
Nektar Therapeutics |
reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
|
|
BRPI0614257A2
(pt)
|
2005-08-04 |
2011-03-15 |
Nektar Therapeutics Al Corp |
conjugados de uma porção de g-csf e um polìmero
|
|
CN101277722A
(zh)
|
2005-08-06 |
2008-10-01 |
王庆华 |
用于预防和治疗ⅰ型糖尿病的组合物及方法
|
|
EP2330124B1
(en)
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
WO2007024700A2
(en)
|
2005-08-19 |
2007-03-01 |
Amylin Pharmaceuticals, Inc. |
Exendin for treating diabetes and reducing body weight
|
|
WO2007033372A2
(en)
|
2005-09-14 |
2007-03-22 |
Mannkind Corporation |
Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
|
|
KR101368525B1
(ko)
|
2005-09-20 |
2014-03-06 |
노파르티스 아게 |
저혈당 증상을 저하시키기 위한 ｄｐｐ-ⅳ 억제제의 용도
|
|
US8759290B2
(en)
|
2005-10-18 |
2014-06-24 |
Biocon Limited |
Oral glucagon-like peptide conjugates for metabolic diseases
|
|
WO2007047922A2
(en)
|
2005-10-19 |
2007-04-26 |
Smartcells, Inc. |
Polymer-drug conjugates
|
|
CN101534846B
(zh)
|
2005-11-07 |
2014-11-05 |
印第安纳大学研究及科技有限公司 |
显示生理学溶解性和稳定性的胰高血糖素类似物
|
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
|
JP2009518315A
(ja)
|
2005-12-02 |
2009-05-07 |
エムディーアールエヌエー，インコーポレイテッド |
グルコース調節ペプチドの上皮透過性を増大させるための製剤処方
|
|
WO2007064691A1
(en)
|
2005-12-02 |
2007-06-07 |
Nabil Habib Lab |
Treatment of cancer and other diseases
|
|
RU2008124109A
(ru)
|
2005-12-08 |
2010-01-20 |
МДРНА, Инк. (US) |
Чресслизистая доставка стабилизированных композиций эксендина
|
|
WO2007075534A2
(en)
|
2005-12-16 |
2007-07-05 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of glp-1
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
JP2009525946A
(ja)
|
2005-12-20 |
2009-07-16 |
デューク・ユニヴァーシティ |
増強された薬理学的性質を有する活性物質を送達するための方法および組成物
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
SI1984009T1
(sl)
|
2006-01-18 |
2013-02-28 |
Qps, Llc |
Farmacevtski sestavki z izboljĺ ano stabilnostjo
|
|
AU2007212147A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
|
US7704953B2
(en)
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
|
CA2646598C
(en)
|
2006-03-21 |
2014-08-19 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
RU2419452C2
(ru)
|
2006-04-13 |
2011-05-27 |
Ипсен Фарма С.А.С. |
ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ hGLP-1, ЭКСЕНДИНА-4 И ИХ АНАЛОГОВ
|
|
KR20150042304A
(ko)
|
2006-04-14 |
2015-04-20 |
맨카인드 코포레이션 |
글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
WO2007133778A2
(en)
|
2006-05-12 |
2007-11-22 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
|
EA200870575A1
(ru)
|
2006-05-26 |
2009-08-28 |
Амилин Фармасьютикалз, Инк. |
Композиции и способы лечения застойной сердечной недостаточности
|
|
EP2021014A1
(en)
|
2006-05-26 |
2009-02-11 |
Brystol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
WO2007148345A2
(en)
|
2006-06-21 |
2007-12-27 |
Biocon Limited |
A method of producing biologically active polypeptide having insulinotropic activity
|
|
PL2494959T3
(pl)
|
2006-07-05 |
2015-06-30 |
Foamix Pharmaceuticals Ltd |
Nośnik ze spienialnego kwasu dikarboksylowego oraz kompozycje farmaceutyczne z nośnikiem
|
|
AU2007278994B2
(en)
|
2006-07-24 |
2013-08-15 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
|
US7928186B2
(en)
|
2006-08-02 |
2011-04-19 |
Phoenix Pharmaceuticals, Inc. |
Cell permeable bioactive peptide conjugates
|
|
AU2007281433A1
(en)
|
2006-08-04 |
2008-02-07 |
Nastech Pharmaceutical Company Inc. |
Compositions for intranasal delivery of human insulin and uses thereof
|
|
KR101200728B1
(ko)
|
2006-08-09 |
2012-11-13 |
인타르시아 세라퓨틱스 인코포레이티드 |
삼투성 전달 시스템 및 피스톤 조립체
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
EP2057188B1
(en)
|
2006-08-17 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Dpp-iv resistant gip hybrid polypeptides with selectable properties
|
|
WO2008023050A1
(en)
*
|
2006-08-25 |
2008-02-28 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
CN102827284B
(zh)
|
2006-11-14 |
2015-07-29 |
上海仁会生物制药股份有限公司 |
带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
|
|
EP2124883A2
(en)
|
2006-12-12 |
2009-12-02 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical formulations and methods for making the same
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
CN101663317A
(zh)
|
2007-01-05 |
2010-03-03 |
CovX科技爱尔兰有限公司 |
胰高血糖素样蛋白-1受体glp-1r激动剂化合物
|
|
CA2674354A1
(en)
|
2007-01-05 |
2008-07-17 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
|
US20090098130A1
(en)
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
RU2432361C2
(ru)
|
2007-01-05 |
2011-10-27 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
|
|
WO2008098212A2
(en)
|
2007-02-08 |
2008-08-14 |
Diobex, Inc. |
Extended release formulations of glucagon and other peptides and proteins
|
|
BRPI0807728A2
(pt)
|
2007-02-15 |
2012-04-17 |
Univ Indiana Res & Tech Corp |
co-agonistas de receptor glucagon/glp-1
|
|
US8420598B2
(en)
|
2007-04-20 |
2013-04-16 |
B & L Delipharm Corp. |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
ES2402172T3
(es)
|
2007-04-23 |
2013-04-29 |
Intarcia Therapeutics, Inc |
Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
|
|
WO2008134425A1
(en)
|
2007-04-27 |
2008-11-06 |
Cedars-Sinai Medical Center |
Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
|
|
US7829664B2
(en)
|
2007-06-01 |
2010-11-09 |
Boehringer Ingelheim International Gmbh |
Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
|
|
US9353170B2
(en)
|
2007-06-08 |
2016-05-31 |
Sanofi-Aventis Deutschland Gmbh |
Long-acting transient polymer conjugates of exendin
|
|
ATE520714T1
(de)
|
2007-06-15 |
2011-09-15 |
Zealand Pharma As |
Glucagonanaloga
|
|
KR20100020516A
(ko)
|
2007-07-10 |
2010-02-22 |
일라이 릴리 앤드 캄파니 |
Ｇｌｐ-1-ｆｃ 융합 단백질 제제
|
|
EP2185178B1
(en)
|
2007-08-03 |
2017-08-23 |
Eli Lilly And Company |
Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
ES2534434T3
(es)
|
2007-08-30 |
2015-04-22 |
Curedm Group Holdings, Llc |
Composiciones y métodos de uso de péptidos proislotes y análogos de los mismos
|
|
CN101842109B
(zh)
|
2007-09-05 |
2014-01-29 |
诺沃-诺迪斯克有限公司 |
用a-b-c-d-衍生的肽和它们的治疗用途
|
|
US20100256056A1
(en)
|
2007-09-07 |
2010-10-07 |
Zheng Xin Dong |
Analogues of exendin-4 and exendin-3
|
|
BRPI0818872A2
(pt)
|
2007-10-24 |
2015-05-05 |
Mannkind Corp |
Método para prevenir efeitos adversos por glp-1
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
JP5813323B2
(ja)
|
2007-10-24 |
2015-11-17 |
マンカインド コーポレイション |
活性薬剤の送達方法
|
|
MX2010004298A
(es)
|
2007-10-30 |
2010-05-03 |
Univ Indiana Res & Tech Corp |
Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
|
|
AU2008318986B2
(en)
|
2007-10-30 |
2014-12-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
|
MX2010005245A
(es)
|
2007-11-16 |
2010-06-01 |
Novo Nordisk As |
Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
|
|
US8710002B2
(en)
|
2007-11-23 |
2014-04-29 |
Michael Rothkopf |
Methods of enhancing diabetes resolution
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
CN102026666B
(zh)
|
2007-12-11 |
2013-10-16 |
常山凯捷健生物药物研发（河北）有限公司 |
促胰岛素肽缀合物制剂
|
|
EP2249853A4
(en)
|
2008-01-30 |
2012-12-26 |
Univ Indiana Res & Tech Corp |
ESTER BASED PEPTIDE PRODRUGS
|
|
HRP20191052T1
(hr)
|
2008-02-01 |
2019-11-01 |
Ascendis Pharma As |
Predlijek koji obuhvaća samocijepajuću poveznicu
|
|
MX349413B
(es)
|
2008-02-06 |
2017-07-19 |
Biocon Ltd |
Medios de fermentacion y procedimientos para los mismos.
|
|
WO2009114959A1
(zh)
|
2008-03-20 |
2009-09-24 |
中国人民解放军军事医学科学院毒物药物研究所 |
可注射用缓释药物制剂及其制备方法
|
|
US20110034385A1
(en)
|
2008-04-07 |
2011-02-10 |
National Institute Of Immunology |
Compositions Useful for the Treatment of Diabetes and Other Chronic Disorder
|
|
KR20110007614A
(ko)
|
2008-05-07 |
2011-01-24 |
메리온 리서치 Ⅲ 리미티드 |
ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법
|
|
WO2009143285A2
(en)
|
2008-05-21 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholestrol and triglycerides
|
|
JP2011523052A
(ja)
|
2008-05-23 |
2011-08-04 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
Ｇｌｐ−１受容体アゴニスト・バイオアッセイ
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
KR101629154B1
(ko)
|
2008-06-13 |
2016-06-21 |
맨카인드 코포레이션 |
건조 분말 흡입기 및 약물 투여 시스템
|
|
BRPI0914889A2
(pt)
|
2008-06-17 |
2015-11-24 |
Otsuka Chemical Co Ltd |
peptídeo glp-1 adicionado de cadeia oligossacarídica
|
|
EP2676673B1
(en)
|
2008-06-17 |
2016-11-16 |
Indiana University Research and Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
CA2727161A1
(en)
|
2008-06-17 |
2009-12-23 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
|
|
EA020326B9
(ru)
|
2008-06-17 |
2015-03-31 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
|
|
CN102131516B
(zh)
|
2008-06-27 |
2016-03-16 |
杜克大学 |
包含弹性蛋白样肽的治疗剂
|
|
EP2303247A4
(en)
|
2008-07-21 |
2012-08-01 |
Syneron Medical Ltd |
TRANSDERMALES SYSTEM FOR THE EXTENDED RELEASE OF INCRETINS AND INCRETIN MIMETIC PEPTIDES
|
|
WO2010013012A2
(en)
|
2008-08-01 |
2010-02-04 |
Lund University Bioscience Ab |
Novel polypeptides and uses thereof
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
EP3228320B1
(de)
|
2008-10-17 |
2019-12-18 |
Sanofi-Aventis Deutschland GmbH |
Kombination von einem insulin und einem glp-1-agonisten
|
|
DK2373681T3
(en)
|
2008-12-10 |
2017-04-24 |
Glaxosmithkline Llc |
PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
|
|
MX2011006314A
(es)
|
2008-12-15 |
2011-09-22 |
Zealand Pharma As |
Analogos de glucagon.
|
|
CA2747155A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
|
EA020537B1
(ru)
|
2008-12-15 |
2014-11-28 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
|
DK2370462T3
(da)
|
2008-12-15 |
2014-09-08 |
Zealand Pharma As |
Glucagon-analoger
|
|
MX2011006524A
(es)
|
2008-12-19 |
2011-08-17 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida.
|
|
CN101538323B
(zh)
|
2009-01-13 |
2012-05-09 |
深圳翰宇药业股份有限公司 |
一种纯化艾塞那肽的方法
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
AU2010221254B2
(en)
|
2009-03-04 |
2014-04-03 |
Mannkind Corporation |
An improved dry powder drug delivery system
|
|
WO2010100241A1
(en)
|
2009-03-05 |
2010-09-10 |
Sanofi-Aventis Deutschland Gmbh |
Drug delivery device with retractable needle
|
|
US8642544B2
(en)
|
2009-04-01 |
2014-02-04 |
Amylin Pharmaceuticals, Llc |
N-terminus conformationally constrained GLP-1 receptor agonist compounds
|
|
WO2010118034A2
(en)
|
2009-04-06 |
2010-10-14 |
Board Of Regents, The University Of Texas System |
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
|
|
AU2010239861B2
(en)
|
2009-04-22 |
2013-07-11 |
Alteogen, Inc |
In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
CN101559041B
(zh)
|
2009-05-19 |
2014-01-15 |
中国科学院过程工程研究所 |
粒径均一的多肽药物缓释微球或微囊制剂及制备方法
|
|
CN102438679B
(zh)
|
2009-05-20 |
2016-03-09 |
赛诺菲-安万特德国有限公司 |
用于药物递送装置中药物容纳筒的塞子
|
|
WO2010133676A1
(en)
|
2009-05-20 |
2010-11-25 |
Sanofi-Aventis Deutschland Gmbh |
A system comprising a drug delivery device and a cartridge provided with a bung and a method of identifying the cartridge
|
|
EP2435061A4
(en)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
|
|
US20120172298A1
(en)
|
2009-06-11 |
2012-07-05 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
|
EP2443146B1
(en)
|
2009-06-16 |
2016-10-05 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
|
CA2766537A1
(en)
|
2009-07-02 |
2011-01-06 |
Angiochem Inc. |
Multimeric peptide conjugates and uses thereof
|
|
US9156901B2
(en)
|
2009-07-13 |
2015-10-13 |
Ditte Riber |
Acylated glucagon analogues
|
|
CN101601646B
(zh)
|
2009-07-22 |
2011-03-23 |
南京凯瑞尔纳米生物技术有限公司 |
治疗糖尿病的鼻腔滴剂及其制备方法
|
|
WO2011011675A1
(en)
|
2009-07-23 |
2011-01-27 |
Zelos Therapeutics, Inc. |
Pharmaceutically acceptable formulations/compositions for peptidyl drugs
|
|
EP2459228B1
(en)
|
2009-07-31 |
2020-03-04 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an insulin linker conjugate
|
|
WO2011017835A1
(en)
|
2009-08-11 |
2011-02-17 |
Nanjing University |
Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
|
JP2013506628A
(ja)
|
2009-09-30 |
2013-02-28 |
グラクソ グループ リミテッド |
延長された半減期を有する薬物融合物及びコンジュゲート
|
|
US20110097386A1
(en)
|
2009-10-22 |
2011-04-28 |
Biodel, Inc. |
Stabilized glucagon solutions
|
|
WO2011049713A2
(en)
|
2009-10-22 |
2011-04-28 |
Biodel Inc. |
Stabilized glucagon solutions
|
|
US9610329B2
(en)
|
2009-10-22 |
2017-04-04 |
Albireo Pharma, Inc. |
Stabilized glucagon solutions
|
|
BR112012011467A2
(pt)
|
2009-10-30 |
2019-09-24 |
Otsuka Chemical Co Ltd |
forma glicosilada de análogo ao glp-1 antigênico.
|
|
EP2496249B1
(en)
|
2009-11-03 |
2016-03-09 |
Amylin Pharmaceuticals, LLC |
Glp-1 receptor agonist for use in treating obstructive sleep apnea
|
|
BR112012011403B8
(pt)
|
2009-11-13 |
2021-05-25 |
Sanofi Aventis Deutschland |
composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
|
|
CA2780460C
(en)
|
2009-11-13 |
2018-09-04 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
|
|
KR102029560B1
(ko)
|
2009-12-15 |
2019-10-07 |
씨리우스 테라퓨틱스, 엘엘씨 |
대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염
|
|
EP2512475A1
(en)
|
2009-12-15 |
2012-10-24 |
Metabolic Solutions Development Company LLC |
Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
|
|
AU2010340058A1
(en)
|
2009-12-15 |
2012-06-21 |
Metabolic Solutions Development Company, Llc |
PPAR-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
|
|
PL2512470T3
(pl)
|
2009-12-15 |
2017-06-30 |
Octeta Therapeutics, Llc |
Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych
|
|
EP2513141B1
(en)
|
2009-12-16 |
2017-03-01 |
Novo Nordisk A/S |
Glp-1 analogues and derivatives
|
|
EP2512503A4
(en)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
|
|
CN102933200B
(zh)
|
2009-12-18 |
2015-11-25 |
莱迪杜德制药公司 |
包含磷脂的单相凝胶组合物
|
|
CN101798588B
(zh)
|
2009-12-21 |
2015-09-09 |
上海仁会生物制药股份有限公司 |
Glp-1受体激动剂生物学活性测定方法
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
|
US20130157953A1
(en)
|
2010-01-20 |
2013-06-20 |
Zealand Pharma A/S |
Treatment of cardiac conditions
|
|
CA2788304A1
(en)
|
2010-01-27 |
2011-08-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
|
WO2011092326A1
(en)
|
2010-02-01 |
2011-08-04 |
Sanofi-Aventis Deutschland Gmbh |
Cartridge holder, drug delivery device and method for securing a cartridge in a cartridge holder
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
KR20130018410A
(ko)
|
2010-03-26 |
2013-02-21 |
노보 노르디스크 에이/에스 |
새로운 글루카곤 유사체
|
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
|
ES2661228T3
(es)
|
2010-05-13 |
2018-03-28 |
Indiana University Research And Technology Corporation |
Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
|
|
US9145451B2
(en)
|
2010-05-13 |
2015-09-29 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhbiting G protein coupled receptor activity
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
BR112012029280A2
(pt)
|
2010-05-20 |
2016-11-29 |
Glaxo Group Ltd |
variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão
|
|
WO2011156407A2
(en)
|
2010-06-09 |
2011-12-15 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonists to treat pancre-atitis
|
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
|
US8636711B2
(en)
|
2010-06-14 |
2014-01-28 |
Legacy Emanuel Hospital & Health Center |
Stabilized glucagon solutions and uses therefor
|
|
JP6385673B2
(ja)
|
2010-06-21 |
2018-09-05 |
マンカインド コーポレイション |
乾燥粉末薬物送達システム
|
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
WO2011162830A2
(en)
|
2010-06-24 |
2011-12-29 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
|
EP2588126A4
(en)
|
2010-06-24 |
2015-07-08 |
Univ Indiana Res & Tech Corp |
AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
|
|
WO2011163473A1
(en)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
|
WO2012012352A2
(en)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
WO2012015975A2
(en)
|
2010-07-28 |
2012-02-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds having stabilized regions
|
|
CN102397558B
(zh)
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
JP6121330B2
(ja)
|
2010-09-28 |
2017-04-26 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続時間が増した改変ポリペプチド
|
|
JP5894174B2
(ja)
|
2010-11-03 |
2016-03-23 |
アレコー リミテッド |
グルカゴンを含む新規組成物
|
|
BR112013011549B1
(pt)
|
2010-11-09 |
2022-01-04 |
Mannkind Corporation |
Composições farmacêuticas compreendendo um agonista do receptor de serotonina e uso das mesmas para tratar sintomas associados com enxaqueca
|
|
EP2460552A1
(en)
|
2010-12-06 |
2012-06-06 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with locking arrangement for dose button
|
|
CN102552883B
(zh)
*
|
2010-12-09 |
2014-02-19 |
天津药物研究院 |
一种多肽复合物、药物组合物、其制备方法和应用
|
|
KR101925620B1
(ko)
|
2010-12-16 |
2018-12-05 |
노보 노르디스크 에이/에스 |
Ｇｌｐ-1 아고니스트 및 ｎ-(8-(2-히드록시벤조일)아미노)카프릴산의 염을 포함하는 고체 조성물
|
|
JP2014504588A
(ja)
|
2010-12-22 |
2014-02-24 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
膵島細胞移植のためのｇｌｐ−１受容体アゴニスト
|
|
ES2713952T3
(es)
*
|
2010-12-22 |
2019-05-24 |
Univ Indiana Res & Tech Corp |
Análogos de glucagón que muestran actividad de receptor de GIP
|
|
CN102532301B
(zh)
|
2010-12-31 |
2014-09-03 |
上海医药工业研究院 |
一类新型的Exendin-4类似物及其制备方法
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN102100906A
(zh)
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
|
US8697644B2
(en)
|
2011-03-10 |
2014-04-15 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of peptide drugs
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
CN106928341B
(zh)
|
2011-03-30 |
2021-06-01 |
上海仁会生物制药股份有限公司 |
定点单取代聚乙二醇化Exendin类似物及其制备方法
|
|
DK2694095T3
(en)
|
2011-04-05 |
2018-05-28 |
Longevity Biotech Inc |
COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
|
|
US9480751B2
(en)
|
2011-04-11 |
2016-11-01 |
Yeda Research And Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
CN102766204B
(zh)
|
2011-05-05 |
2014-10-15 |
天津药物研究院 |
胰高血糖素样肽-1突变体多肽及其制备方法和其应用
|
|
JP6284471B2
(ja)
|
2011-05-18 |
2018-02-28 |
メデリス ダイアビーティーズ，エルエルシー |
インスリン抵抗性のための改善されたペプチドの調合薬
|
|
JP2014521594A
(ja)
|
2011-05-25 |
2014-08-28 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
長持続期間デュアルホルモンコンジュゲート
|
|
UA113626C2
(xx)
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
|
BR112013031794B1
(pt)
|
2011-06-10 |
2020-11-10 |
Hanmi Science Co., Ltd |
peptídeo derivados de oxintomodulina e seu uso, polinucleotídeo, composição farmacêutica e seu uso e método para prevenção ou tratamento da obesidade compreendendo os mesmos
|
|
WO2012167744A1
(en)
|
2011-06-10 |
2012-12-13 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
|
|
CA3080189C
(en)
|
2011-06-17 |
2023-01-17 |
Hanmi Science Co., Ltd. |
A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
|
|
CN103974715A
(zh)
|
2011-06-17 |
2014-08-06 |
哈洛齐梅公司 |
乙酰透明质酸降解酶的稳定制剂
|
|
HRP20170890T1
(hr)
|
2011-06-22 |
2017-09-08 |
Indiana University Research And Technology Corporation |
Suagonisti glukagonskog/glp-1 receptora
|
|
JP6184404B2
(ja)
|
2011-06-22 |
2017-08-23 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
グルカゴン／ｇｌｐ−１レセプターコアゴニスト
|
|
CN103906528A
(zh)
|
2011-06-24 |
2014-07-02 |
安米林药品有限责任公司 |
用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
|
|
KR101357117B1
(ko)
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
|
US9944687B2
(en)
|
2011-07-04 |
2018-04-17 |
Imperial Innovations Limited |
Compounds and their effects on feeding behaviour
|
|
WO2013009545A1
(en)
|
2011-07-08 |
2013-01-17 |
Amylin Pharmaceuticals, Inc. |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
|
KR101810055B1
(ko)
|
2011-08-10 |
2017-12-18 |
아도시아 |
하나 이상의 유형의 기저 인슐린의 주사액
|
|
JP6169079B2
(ja)
|
2011-08-24 |
2017-07-26 |
フェーズバイオ ファーマシューティカルズ，インコーポレイテッド |
徐放のための活性剤の製剤
|
|
CN103189389B
(zh)
|
2011-09-03 |
2017-08-11 |
深圳市健元医药科技有限公司 |
新的glp‑ⅰ类似物及其制备方法和用途
|
|
CA2849673A1
(en)
|
2011-09-23 |
2013-03-28 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
KR101967941B1
(ko)
|
2011-10-28 |
2019-04-10 |
사노피-아벤티스 도이칠란트 게엠베하 |
제2형 당뇨병 치료 프로토콜
|
|
CN102363633B
(zh)
|
2011-11-16 |
2013-11-20 |
天津拓飞生物科技有限公司 |
胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
|
|
WO2013074910A1
(en)
|
2011-11-17 |
2013-05-23 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
|
CA2852716C
(en)
|
2011-11-29 |
2015-11-17 |
Jurox Pty Ltd |
Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
|
|
EP2791160B1
(en)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
|
WO2013093720A2
(en)
|
2011-12-22 |
2013-06-27 |
Pfizer Inc. |
Anti-diabetic compounds
|
|
AP2014007797A0
(en)
*
|
2011-12-23 |
2014-07-31 |
Boehringer Ingelheim Int |
Glucagon analogues
|
|
WO2013101749A1
(en)
|
2011-12-29 |
2013-07-04 |
Latitude Pharmaceuticals, Inc. |
Stabilized glucagon nanoemulsions
|
|
EP2814461B1
(fr)
|
2012-01-09 |
2019-07-24 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
|
|
WO2013148871A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides
|
|
EP2844269A4
(en)
|
2012-03-28 |
2016-01-06 |
Amylin Pharmaceuticals Llc |
TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES
|
|
HK1206612A1
(en)
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
|
CA2868393A1
(en)
|
2012-04-02 |
2013-10-10 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
CN102649947A
(zh)
|
2012-04-20 |
2012-08-29 |
无锡和邦生物科技有限公司 |
一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用
|
|
WO2013163162A1
(en)
|
2012-04-24 |
2013-10-31 |
Amylin Pharmaceuticals, Llc |
Site-specific enzymatic modification of exendins and analogs thereof
|
|
US20130289241A1
(en)
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
WO2013182217A1
(en)
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
US9453064B2
(en)
|
2012-05-03 |
2016-09-27 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
|
EP2664374A1
(en)
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
|
CN103421094A
(zh)
*
|
2012-05-24 |
2013-12-04 |
上海医药工业研究院 |
一种具有epo类似活性的多肽化合物
|
|
US20150174209A1
(en)
|
2012-05-25 |
2015-06-25 |
Amylin Pharmaceuticals. Llc |
Insulin-pramlintide compositions and methods for making and using them
|
|
AR091422A1
(es)
*
|
2012-06-14 |
2015-02-04 |
Sanofi Sa |
Analogos peptidicos de la exendina 4
|
|
AR091478A1
(es)
*
|
2012-06-21 |
2015-02-04 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa)
|
|
MX354163B
(es)
|
2012-07-12 |
2018-02-15 |
Mannkind Corp |
Sistemas y métodos de suministro de fármaco en polvo seco.
|
|
AR091866A1
(es)
|
2012-07-23 |
2015-03-04 |
Zealand Pharma As |
Analogos del glucagon
|
|
AR094821A1
(es)
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
US20150224176A1
(en)
|
2012-08-14 |
2015-08-13 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
US20150258198A1
(en)
|
2012-08-14 |
2015-09-17 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
CN102816244A
(zh)
|
2012-08-23 |
2012-12-12 |
无锡和邦生物科技有限公司 |
一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
|
|
CN102827270A
(zh)
|
2012-09-13 |
2012-12-19 |
无锡和邦生物科技有限公司 |
一种聚乙二醇化艾塞那肽衍生物及其用途
|
|
US9546205B2
(en)
|
2012-09-17 |
2017-01-17 |
Imperial Innovations Limited |
Peptide analogues of glucagon and GLP1
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
UA116217C2
(uk)
*
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
TWI816739B
(zh)
|
2012-11-06 |
2023-10-01 |
南韓商韓美藥品股份有限公司 |
包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
JP6525456B2
(ja)
|
2012-11-20 |
2019-06-05 |
メデリス ダイアビーティーズ，エルエルシー |
インスリン抵抗性のための改善されたペプチド製剤
|
|
TWI674270B
(zh)
|
2012-12-11 |
2019-10-11 |
英商梅迪繆思有限公司 |
用於治療肥胖之升糖素與glp-1共促效劑
|
|
HK1211231A1
(en)
|
2012-12-21 |
2016-05-20 |
Sanofi |
Exendin-4 derivatives
|
|
CN103908657A
(zh)
|
2012-12-31 |
2014-07-09 |
复旦大学附属华山医院 |
胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
|
|
JP2016512213A
(ja)
|
2013-03-14 |
2016-04-25 |
メディミューン リミテッド |
肥満の治療のためのペグ化グルカゴン及びｇｌｐ−１コアゴニスト
|
|
WO2014158900A1
(en)
|
2013-03-14 |
2014-10-02 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
|
WO2014152460A2
(en)
|
2013-03-15 |
2014-09-25 |
Indiana University Research And Technology Corporation |
Prodrugs with prolonged action
|
|
MY174727A
(en)
|
2013-04-18 |
2020-05-11 |
Novo Nordisk As |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
|
JP2014227368A
(ja)
|
2013-05-21 |
2014-12-08 |
国立大学法人帯広畜産大学 |
糖尿病および高血糖状態の処置のためのグルカゴンアナログ
|
|
CN103304660B
(zh)
|
2013-07-12 |
2016-08-10 |
上海昂博生物技术有限公司 |
一种利拉鲁肽的合成方法
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
CN119119233A
(zh)
|
2013-10-17 |
2024-12-13 |
西兰制药公司 |
酰化胰高血糖素类似物
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
WO2015067716A1
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／升糖素受體促效劑
|
|
EP3080151A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Exendin-4 peptide analogues
|
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
EP3080155A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
|
CN103665148B
(zh)
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
|
CN103980358B
(zh)
|
2014-01-03 |
2016-08-31 |
杭州阿诺生物医药科技股份有限公司 |
一种制备利拉鲁肽的方法
|
|
US9839692B2
(en)
|
2014-01-09 |
2017-12-12 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
WO2015104311A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
CN104926934B
(zh)
|
2014-09-23 |
2016-11-09 |
蒋先兴 |
胃泌酸调节素类似物
|